Cigna's Q2 2026: Raised Guidance, AI-Led Innovation, and the Signature Model's Long Game

Evernorth's specialty strength and the Signature transition drive a confident outlook, while AI and IDR become new watchwords.

CI · Earnings Call · 2026-07-30

Strong Quarter, Raised Guidance

The Cigna Group delivered a beat-and-raise second quarter, with pretax adjusted earnings across both Evernorth and Cigna Healthcare coming in ahead of expectations. Total revenues reached $71.7 billion, and adjusted EPS of $7.78 propelled management to lift full-year 2026 guidance to at least $30.45. The tone was confident: “we delivered strong performance in the second quarter as we continue to execute at a high level, drive results and accelerate momentum across our enterprise.” — Brian Evanko, President and Chief Executive Officer · 2026-07-30 The earnings power is clear: Specialty & Care Services pretax earnings grew 22% year-over-year, driven by faster-than-expected biosimilar and specialty generic adoption, plus contributions from the Shields Health Solutions investment. This is a continuation of a well-telegraphed story—the strength in specialty has been a recurring theme across prior calls. What's telling is the offsetting softness in Pharmacy Benefit Services (PBS), which declined as anticipated due to proactive large-client renewals and investments in the new Signature model. As CFO Ann Dennison noted, the economic shift is deliberate: “the economic shift from pharmacy benefit services to the Specialty & Care line.” — Ann Dennison, Chief Financial Officer · 2026-07-30

Signature, AI, and the Forward-Looking Momentum

The Signature rebate-free model is the strategic linchpin. Management cited strong 2027 selling-season traction—new business already secured exceeds the prior two years combined. This echoes the Q1 2026 commentary: “the market feedback thus far as it relates to our new rebate-free [Signature] model has been positive.” — Brian Evanko, President and Chief Operating Officer (incoming CEO) · 2026-04-30 With the model set to scale in 2028, Cigna is positioning itself as the industry's standard-bearer for transparency and patient-centric pricing. What's genuinely new this quarter is the AI narrative. CEO Brian Evanko introduced Pharmacy Forward, an AI-powered program expected to cut time to therapy in half, and expanded AI-enabled care coordination that could support 20% more customers with emerging complex health needs. This is a fresh—and compelling—thematic lens for the company, moving beyond cost-takeout to personalized care delivery.

Our AI approach is built on a simple principle, start with the customer and patient and identify where innovation can drive the most meaningful impact for them.
Brian Evanko, President and Chief Executive Officer · 2026-07-30

Headwinds and Watch Items

Not everything is smooth. The GLP-1 moderation—both coverage and utilization—is a slight headwind, but management says it's more than offset by specialty strength. More concerning is the IDR mechanism, which Brian Evanko described as seeing "clear abuses": “we're seeing some clear abuses of the IDR vehicle in practice.” — Brian Evanko, President and Chief Executive Officer · 2026-07-30 He cited $15 billion of industry spending processed through IDR in 2025, much of it "wasteful or abusive," though the impact on Cigna remains manageable within planning assumptions. On the medical side, risk adjustment confirmed expectations, with Ann Dennison noting: “the release of the 2025 final risk adjustment data and also the June weekly update for 2026 confirmed our risk adjustment position.” — Ann Dennison, Chief Financial Officer · 2026-07-30 The company also reaffirmed high single-digit cost trends and the stop-loss recapture plan progressing in line. The stock itself has been range-bound—flat over the last 90 days and still ~24% below its 2024 peak. With fundamentals showing operating margin at 3.4%, the market appears to be waiting for proof that the Signature transition and AI investments will translate into durable EPS growth. The raised guidance is a step, but the real test comes at Investor Day in September.